Stephen Betz - Crinetics Pharmaceuticals Co-Founder, Vice President - Biology
| CRNX Stock | USD 57.67 0.90 1.59% |
President
Dr. Stephen F. Betz, Ph.D., is Vice President Biology of the Company. Previously, from June 2003 to May 2009, he was Director of Endocrinology and Metabolism at Neurocrine Biosciences, Inc., where he worked on the discovery and development of GnRH receptor antagonists and nonpeptide modulators of other endocrine targets. Prior to Neurocrine, from 2001 to 2003, he led laboratory efforts at GeneFormatics, Inc., and from 1996 to 2000, he worked in pharmaceutical discovery at Abbott Laboratories, including structureguided drug design, assay development, and compound screening in the Research Nuclear Magnetic Resonance Group. From 1993 to 1996, he worked at the Dupont Merck Pharmaceutical Company focusing on protein engineering and design. He holds a B.S. in chemistry from the University of Delaware and a Ph.D. in chemistry from the University of North Carolina at Chapel Hill. since 2009.
| Age | 58 |
| Tenure | 15 years |
| Professional Marks | Ph.D |
| Address | 6055 Lusk Boulevard, San Diego, CA, United States, 92121 |
| Phone | 858 450 6464 |
| Web | https://www.crinetics.com |
Stephen Betz Latest Insider Activity
Tracking and analyzing the buying and selling activities of Stephen Betz against Crinetics Pharmaceuticals stock is an integral part of due diligence when investing in Crinetics Pharmaceuticals. Stephen Betz insider activity provides valuable insight into whether Crinetics Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Crinetics Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Crinetics Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Stephen Betz over three months ago Disposition of 3000 shares by Stephen Betz of Crinetics Pharmaceuticals at 53.19 subject to Rule 16b-3 | ||
Stephen Betz over three months ago Disposition of 3000 shares by Stephen Betz of Crinetics Pharmaceuticals at 45.37 subject to Rule 16b-3 | ||
Stephen Betz over six months ago Disposition of 3000 shares by Stephen Betz of Crinetics Pharmaceuticals at 47.49 subject to Rule 16b-3 |
Crinetics Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2429) % which means that it has lost $0.2429 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4026) %, meaning that it created substantial loss on money invested by shareholders. Crinetics Pharmaceuticals' management efficiency ratios could be used to measure how well Crinetics Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.35 in 2024. Return On Capital Employed is likely to drop to -0.4 in 2024. At this time, Crinetics Pharmaceuticals' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 382 M in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Similar Executives
| Found 2 records | PRESIDENT Age | ||
| Rodolfo Chaparro | Cue Biopharma | 51 | |
| Anish Suri | Cue Biopharma | 50 | |
Management Performance
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.24 |
Crinetics Pharmaceuticals Leadership Team
Elected by the shareholders, the Crinetics Pharmaceuticals' board of directors comprises two types of representatives: Crinetics Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Crinetics. The board's role is to monitor Crinetics Pharmaceuticals' management team and ensure that shareholders' interests are well served. Crinetics Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Crinetics Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeff Knight, Chief Officer | ||
| James Hassard, Chief Officer | ||
| Adriana MBA, Chief Officer | ||
| Gayathri Diwakar, Head Relations | ||
| Stephen Betz, Co-Founder, Vice President - Biology | ||
| Dana MD, Chief Officer | ||
| Robert MD, Senior Affairs | ||
| Marc Wilson, Chief Officer | ||
| Kevin Capps, Head Property | ||
| Scott Struthers, CEO, Co-Founder, Director | ||
| Alan MD, Chief Endocrinologist | ||
| Garlan Adams, General Secretary | ||
| Chris MBA, Chief Officer | ||
| Marc CPA, Chief Officer |
Crinetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Crinetics Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (295.25) % | ||||
| Current Valuation | 4.54 B | ||||
| Shares Outstanding | 92.74 M | ||||
| Shares Owned By Insiders | 1.79 % | ||||
| Shares Owned By Institutions | 94.70 % | ||||
| Number Of Shares Shorted | 6.5 M | ||||
| Price To Earning | (12.03) X | ||||
| Price To Book | 6.42 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.